OV’s method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal

On June 4, 2019 Oncology Venture A/S ("OV" or "the Company") reported that an e-abstract has been published in Journal of Clinical Oncology – an ASCO (Free ASCO Whitepaper) Journal –, describing that DRP (Drug Response Prediction) is able to predict which breast cancer patients will be high likelihood responders to neoadjuvant (early) treatment with doxorubicin (Press release, Oncology Venture, JUN 4, 2019, View Source [SID1234536872]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neoadjuvant treatment of breast cancer is an important remedy if the tumors are responding adequately. The current lack of adequate biomarker guidance results in many patients receiving chemotherapy without an efficient antitumor effect. The e-abstract in Journal of Clinical Oncology reports positive results from a study of Oncology Venture’s multigene mRNA-based technology for drug response prediction (DRP). DRP has been thoroughly validated in other settings, most recently in prediction of epirubicin – a sister molecule – efficacy in advanced breast cancer [1].

Based on analyses performed by the authors, it is concluded that DRP can predict which patients will be high likelihood responders to neoadjuvant doxorubicin. Modern multigene technologies may help assist clinicians in choosing between upfront surgery or neoadjuvant chemotherapy.

The e-abstract "Doxorubicin response prediction in neoadjuvant breast cancer therapy" can be accessed her

1. Buhl ASK, et al. (2018): Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study. Breast cancer research and treatment. doi: 10.1007/s10549-018-4918-4.

For further information, please contact:

For investor inquiries
Ulla Hald Buhl, IR & Communications
E-mail: [email protected]
Telephone +45 21 70 10 49 For media inquiries
Thomas Pedersen, Carrotize PR & Communications

E-mail: [email protected]
Telephone +45 60 62 93 90